NF1 is a nervous system disorder that affects ... The drugmaker also warned that Gomekli may harm an unborn baby. Women should take a pregnancy test before starting treatment and use birth control ...

Neurofibromatosis type 1 (NF1) is the most common of the three types of neurofibromatosis and is also one of the most common inherited neurological disorders, affecting about 1 in 3,000 people ...

Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable to complete surgical resection are indicated in the approval.

Gomekli is the first medication approved for both adult and pediatric patients with NF1-PN. The Food and Drug Administration (FDA) has approved Gomekli ™ (mirdametinib) for the treatment of ...

Opens in a new tab or window The FDA on Tuesday approved mirdametinib (Gomekli) for adults and kids ages 2 and up with neurofibromatosis type 1 (NF1). Approval of the MEK inhibitor is specifically ...

The disease, neurofibromatosis type 1 (NF1), is technically not cancer as the tumors that form are benign. But NF1 can lead to cancers. Even if a patient’s tumors aren’t cancerous, they are ...